• Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference
• CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization
• The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently participated in three investor conferences during May – The Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. These conferences provided Clene with the opportunity to present its lead drug candidate CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization.

The Mizuho Neuroscience Summit 2024 took take place on May 20-21 at the Boston Harbor Hotel in Boston, MA (https://ibn.fm/yVw8Y). This event, organized by Mizuho Americas, is part of their initiative to explore promising investment trends and breakthroughs in the field of neuroscience. The summit included panel presentations and opportunities for one-on-one meetings, providing a platform for leading medical experts and biopharmaceutical companies to discuss advancements in treating neurodegenerative and psychiatric diseases​.

The inaugural summit in 2023 focused on key topics such as Alzheimer’s disease treatment, neurodegenerative diseases, and emerging psychiatric treatments, featuring insights from top venture capital investors and biotech markets. This kind of event is crucial as it brings together expertise from various areas of neuroscience to foster discussions that could lead to new collaborations and innovations in the field​.

The Benchmark 2024 Healthcare House Call Virtual Conference occurred May 21-22, 2024 (https://ibn.fm/nsz6r). This virtual event was designed to facilitate one-on-one meetings between participants, offering a direct and personalized way to engage with healthcare experts and professionals. The format of this conference supports in-depth discussions and networking opportunities in a virtual setting, making it accessible for a wide audience regardless of geographic location. This event is part of a broader series of conferences that focus on the healthcare sector, providing insights and updates on various healthcare topics and trends.

The Virtual A.G.P. Healthcare Conference took place May 22, 2024 (https://ibn.fm/pkTaR). This conference was set up as a virtual event, providing a platform for participants to engage in one-on-one meetings with healthcare professionals, investors, and industry experts. The virtual format of this conference is particularly designed to cater to a global audience, enabling stakeholders from various parts of the world to connect, share insights, and discuss the latest trends and developments in the healthcare sector without the need for travel​.

The company’s presentation about CNM-Au8 showcased it as an innovative treatment involving a suspension of gold nanocrystals aimed at addressing neurodegeneration. It works by targeting the core issues prevalent in diseases like ALS, MS, and Parkinson’s—specifically mitochondrial dysfunction, NAD+ decline, and oxidative stress. Its catalytic action helps maintain cell metabolism, reduce harmful reactive oxygen species, and promote protein homeostasis, thereby offering neuroprotective and remyelinating benefits.

The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported. This highlights its potential as a safe adjunct to other treatments, enhancing cell function and survival, particularly noted in clinical ALS trials.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region
• PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies
• PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide resources to ensure a steady supply of suramin to endemic regions

PaxMedica (NASDAQ: PXMD), a biopharmaceutical firm dedicated to advancing treatments for neurological disorders, recently announced that it has received an urgent plea from the Ministry of Health (“MOH”) of Malawi. The MOH is requesting emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region (https://ibn.fm/wWNpQ).

Following the recent completion of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin), PaxMedica has promptly brought this urgent request to the attention of the U.S. Food and Drug Administration (“FDA”). The company aims to assess any potential impact on its ongoing development program and plans for submitting a New Drug Application (“NDA”) for PAX-101. PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, commonly called “sleeping sickness”, transmitted by tsetse flies.

Howard Weisman, Chairman and CEO of PaxMedica, emphasized the significance of the MOH’s request, highlighting the critical situation faced by countries vulnerable to the fatal disease TBr HAT. He underscored the continued necessity of suramin as the standard treatment for Stage 1 of the infection, particularly citing the Malawi dosing protocol used for nearly a century to save lives in the region.

Weisman also noted the potential public health benefit of having multiple global manufacturers of drugs like suramin, as it could create diverse supply chains and ensure a steady drug supply. PaxMedica’s Real World retrospective evidence, including the HAT-301 clinical study of TBR HAT patients treated with suramin between 2000 and 2020, involved a significant number of cases from Malawi. This underscores the importance of Malawi’s contribution to PaxMedica’s research efforts on PAX-101.

PaxMedica is actively engaging with regulatory authorities in the U.S. and Malawi to address the emergency request from the Malawi Ministry of Health. Additionally, the company is collaborating with the FDA to determine the optimal path for submitting the PAX-101 NDA for regulatory approval. PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide resources to ensure a steady supply of suramin to endemic regions.

Wiseman also said [that the] “FDA has agreed that having more than one global manufacturer of drugs like suramin could provide public health benefit by creating multiple supply chains and would help ensure a steady supply of the drug product.”

The most recent Bell2Bell Podcast sheds light on PaxMedica’s commitment to addressing the critical storage of medications required to combat the life-threatening sleeping sickness crisis in Malawi. The podcast features PaxMedica’s CEO and Malawi Health Official, Dr. Marshal Lemerani, discussing the urgency of the request made for suramin with host Stuart Smith. The full podcast can be found at https://ibn.fm/VgbgO.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• The 5th Annual Reg A & Crowdfunding Conference will take place at New York’s luxurious Westchester Country Club on June 20
• The fifth annual conference will play host to investors, entrepreneurs and financiers as we to delve into the latest trends within the equity capital markets industry
• This year’s conference will feature a number of keynote presentations and speakers, including on topics such as the structuring and efficient marketing of Reg A+ and Crowdfunding deals

Learn from (and network with) experts who raise capital with these powerful tools

Equity capital markets have long been an attractive source of growth capital for companies seeking to finance further expansion, particularly in a scenario where debt financing has grown increasingly expensive to obtain. A dynamic landscape of equity crowdfunding avenues has emerged to respond to this capital requirement, with entrepreneurs seeking increasingly innovate manners through which to access capital, matching their needs with investors seeking opportunities for growth. Introduced through the 2012 JOBS Act, Regulation A+ (Reg A+) funding has emerged as one of the fastest growing funding mechanisms for emerging companies today. Permitting companies to gain exposure and raise up to $75 million annually through the sale of securities to both, accredited and non-accredited investors, the emergence of Reg A+ equity capital raises has further democratized access to potential returns.

From 2021-2022 period, Reg A+ issuers raised $1.8 billion through a wide array of qualifying offerings. The process of accessing this funding avenue has historically been complex. A lengthy process required to gain SEC qualification, coupled with the difficulty in carrying out a successful marketing campaign needed to attract investors has been a constraint for some companies seeking to raise assets through Reg A. However, companies that are able to navigate the regulatory process and execute solid marketing campaigns have raised significant capital while avoiding many of the pitfalls associated with traditional capital-raise tools.

The upcoming Reg A & Crowdfunding Conference has been designed to provide prospective corporate issuers and financiers with a venue to come together to help facilitate the regulatory hurdles and obstacles traditionally associated with these capital raise methods.

If you are the executive of a private company thinking about a Reg A or Crowdfunding campaign, you may be eligible for a free ticket to the conference. Learn more.

With over 21 years of experience and having hosted more than 200 conferences, seminars and webcasts on a variety of financial topics, DealFlow Events is uniquely prepared to deliver the actionable information you need at the 5th Annual Reg A & Crowdfunding Conference at New York’s Westchester Country Club on June 20.

This is the largest annual conference of its kind, bringing together a broad array of online investment platforms, brokers, legal and financial advisors, investors and other dealmakers involved within the space. The Reg A & Crowdfunding Conference has also historically been a must-attend event for hundreds of private and public companies seeking to raise capital. 

The 2024 Conference expands further with an increased focus on online deal-marketing tactics. Attendees will glean insights from experts on deal structures, fees and expenses, as well as the continuously evolving regulatory landscape.

This year’s conference will touch upon a range of topics, including an overview on the current environment for raising capital through Reg A and Crowdfunding deals, why Crowdfunding has been an attractive fundraising avenue when venture debt and business loans have not been an option, how to determine whether to pursue a Reg A or Crowdfunding campaign, and how to increase the visibility and marketing of a Reg A and Crowdfunding offering in the current financial climate.

Both of these options offer the potential for a faster capital raise at far lower expense than a traditional IPO.

Register now while seats are still available. This event routinely reaches capacity. We look forward to seeing you soon at The Westchester Country Club.

Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking.

Specific areas of discussion will include:

• Targets for novel drug development
• Toxicology studies and considerations
• The dosage debate and new evidence
• Second generation psychedelic drug design
• FDA regulatory guidance

The speaker panel consists of an impressive line-up of leaders and dignitaries who will share important insights and strategies on a number of industry topics. This includes the latest discoveries, psychedelic therapeutics, and clinical trials, offering a fresh perspective and critical knowledge to attendees.

Speaker topics will cover:

• Clinical Trial Design
• Legal Issues
• Intellectual Property
• Regulatory Guidance
• Psychedelic Drug Delivery
• Commercialization
• Emerging Preclinical Science
• New Clinical Data

This conference offers an excellent forum for newcomers as well as veterans for the discovery and exchange of knowledge in the world of psychedelics and therapeutics.

The event commences with opening remarks from the chairperson, Peter Hendricks, Ph.D., Professor, Department of Psychiatry, University of Alabama Birmingham. Attendees will get answers to some vital issues related to ways of optimizing psychedelic trials and scaling trail delivery while still being consistent. Other important topics include discussions on studies being conducted for the treatment of Schizophrenia, postpartum depression, distress in cancer, and more.

After the morning refreshment break, the conference will resume with a panel discussion navigating the challenges in research and compliance with the Federal Analogue Act.

The conference is being held at the luxurious Revere Hotel Boston Common, 200 Stuart Street, Boston, MA (www.reverehotel.com), described as “Shaped by local culture and the rebellious, independent spirit of Boston, Revere Hotel Boston Common is a downtown refuge for the adventurous and curious. Immerse yourself in authentic local experiences at our original Back Bay hotel, located steps from Boston’s Theater District, Newbury Street and Copley Square.”  

To register and learn more, please visit https://ibn.fm/FCMNc.

DGE invites medical affairs and healthcare professionals to attend the 8th Digital Strategy & Innovation For Medical Affairs summit in Philadelphia on June 5-6, 2024. Experts attending the conference will offer insights to leverage digital technology for building patient and caregiver relationships, and for maintaining market position.

The summit is organized by Dynamic Global Events (“DGE”), a life science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotechnology, healthcare, medical devices, and allied industries.

The event agenda covers:

• Incorporating AI into patient outreach
• Identifying the most important tools needed to create a digital engagement medical affairs strategy
• Crafting medical animation for enriching HCP initiatives
• Using digital technologies to monitor and analyze the patient voice
• Increasing engagement and reach by including digital leaders in the company’s digital marketing journey

The event focuses on discovering and discussing new methods of digital engagement. Experts conducting speaker sessions will speak about developing the right vendor and data management relationships, and also about training medical teams with the latest digital technologies to increase patient engagement for future success.

Attendees of DGE events enjoy a multitude of benefits such as targeted networking as well as access to presentations after the event. The summit offers a phenomenal opportunity to learn about the latest trends and strategies for digital transformation. Professionals and executives get to showcase their services and business ideas on a prestigious conference platform attended by the eminent leaders of the industry.

To learn more, please visit https://ibn.fm/PvsSS.

• SenesTech reported record Q1 2024 revenue of $415,000, an increase of 78% compared to Q1 2023 and a 41% sequential increase from Q4 2023
• The company attributes this growth to the introduction in January 2024 of Evolve(TM), its soft-bait product featuring breakthrough, next-generation technology that targets rat populations by using non-lethal methods to restrict fertility
• SenesTech is anticipating additional growth following the completion of an efficacy study providing data requested by certain state and international regulators, as this could open new markets that were previously inaccessible
• In May, the company also launched Evolve(TM) Mouse, a soft-bait product to control mouse infestations; SenesTech expects Evolve(TM) Mouse, which doubles its addressable market opportunity, to be a key driver of growth throughout the rest of the year

SenesTech (NASDAQ: SNES), the provider of a one-of-a-kind technology for controlling animal pest populations through fertility control and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R), recently announced financial results for the first quarter of 2024, ended March 31, 2024, and released operational highlights (https://ibn.fm/kxzyA). During this reporting period, the company reported record revenue of $415,000, a year-over-year increase of 78% compared to the first quarter of 2023. This was also a 41% increase sequentially from the fourth quarter of 2023.

“The key driver [for this growth] has been the introduction of Evolve(TM), our all-new soft-bait product launched in January of this year, which has quickly become the company’s biggest selling product, contributing more than 50% of the first quarter revenue,” said SenesTech President and CEO Joel Fruendt during a conference call accompanying the release of the results.

But Fruendt noted that this “outstanding growth reflected regulatory approval of Evolve in only 30 states,” pointing to the potential for even more growth in the future. “There were several states, including high potential states such as Florida, that required an efficacy study before approval. That efficacy study is now complete, which bodes well for acceptance by the remaining states and further accelerated growth in Q2,” explained Fruendt.

Completed at an independent research facility in April, the efficacy study yielded positive results, which confirmed a significant reduction in litter size through only one breeding cycle. Describing these results, Fruendt said, “This indicates a 50% reduction in population over six months, compared to leaving the population untreated and 90% plus after one year integrated into an IPM program. We will now start some longer-term field trials at customer locations, and we fully expect the efficacy to increase significantly over multiple litters with increased consumption and real-world conditions.”

The company expects Evolve to be the product of choice for rodent population control, especially now that the efficacy study has provided the data requested by certain state and international regulators. And with the New York City Council introducing a proposal for the deployment of “EPA-approved rat birth control” to address rat infestations, SenesTech appears well poised as the only manufacturer of such product, given the city’s high visibility.

Evolve is the first and only soft bait product featuring breakthrough, next-generation technology that targets rat populations by using non-lethal methods to restrict fertility. The product focuses on the rapid reproduction of rats by reducing or eliminating the fertility of rats, thus addressing the fundamental driver of rodent overpopulation. In addition, it has a shelf life of one year, making it an excellent rodent control product for distribution, and is available at a competitive price compared to traditional rodenticides, according to Fruendt.

“Evolve has proven to be a very versatile product that is perfect for many distribution channels that focus on our target market. To keep focus on each of these areas, we have developed our six-channel strategy for distribution. Our six channels are e-commerce, international, agri-business, pest management, industrial, and retail,” explained Fruendt.

Accordingly, SenesTech has secured distribution, stocking agreements, and initial purchase orders with several grain management and open-field agricultural distributors, and expanded agreements with leading distributors in the pest management industry, including DIY Pest Control and Veseris. SenesTech has also extended its geographic reach, with opportunities in Australia, Hong Kong, Macau, New Zealand, Singapore, The Netherlands, and the United Arab Emirates (“UAE”).

Moreover, SenesTech is launching a dedicated Amazon store in May to expand distribution to the do-it-yourself market. The company has also expanded its sales and marketing efforts through agreements with manufacturers’ rep groups to bring its products to retailers and industrial suppliers, who will, in turn, potentially provide access to the facilities management and food safety markets.

Another key highlight for the company was the launch of Evolve Mouse, a soft-bait product that utilizes the same revolutionary breakthrough fertility solution as Evolve to control mouse infestations. Product shipments began in May 2024, with DIY Pest Control committing to a sizable pre-order. The company expects Evolve Mouse to be a key driver of growth throughout the rest of the year.

“[Evolve Mouse] effectively doubles our addressable market opportunity. It has been estimated that U.S. rodent pest management product sales, over half of which target mouse infestations, are more than $1 billion annually and growing,” explained Fruendt. He separately noted in the press release announcing the Q1 2024 results that Evolve Mouse, SenesTech’s first population control solution outside of rats, highlights the first step in the company’s long-term product evolution roadmap to bring fertility control solutions to a wide variety of animal pests.

“We are extremely pleased with the progress the team has made in 2024 and look forward to the positive impact the many recent initiatives we have implemented will produce,” concluded Fruendt in the press release.

To listen to the recorded webcast of the conference call, visit https://nnw.fm/LRBbT https://ibn.fm/ho7Vv (registration required).

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• The HealthLynked platform provides secure and quick access for patient/doctor records communication, supporting all types of health related utilization, including telemedicine and remote student applications
• University health clinics often face challenges when transferring medical records – and this limits coordinated care for students
• The HealthLynked platform provides a streamlined approach to medical records access, allowing students to securely share their health information with relevant parties

HealthLynked (OTCQB: HLYK) is a company on a mission to build a superior healthcare system through the efficient integration of patient histories, genetic data, and demographic insights, into a sophisticated AI-driven platform that streamlines patient care and also analyzes trends across large populations to proactively manage health outcomes.

One aspect of this mission is to solve a problem that often plagues the almost 20 million students enrolled in universities and colleges.  Universities often face challenges when transferring medical records – and this limits coordinated care for student patients across the board. HealthLynked’s solution centralizes records and makes them accessible across multiple care settings.

Transferring medical records has always been a tedious task, especially for students with complex health needs. Concerned parents often find themselves navigating through complex and confusing HIPAA regulations to access vital information about their child’s health. Ensuring the smooth transition of medical records upon graduation without overburdening clinic staff has remained a pressing issue, one that HealthLynked solves.

HealthLynked is a game-changer when it comes to student healthcare. The platform provides a streamlined approach to medical records access, allowing students to securely share their health information with relevant parties. This ensures proper coordination between university clinics and home-based specialists, significantly reducing the risk of errors or medication interactions, particularly for students managing multiple prescriptions.

The platform’s innovative co-management feature offers parents peace of mind by granting them access to their child’s health information with consent. This not only fosters better communication with university clinics but also ensures compliance with stringent HIPAA regulations, addressing a longstanding concern among parents.

For students with complex health needs requiring specialized care or mental health services, HealthLynked facilitates seamless sharing of medical history between university and home-based providers. This coordinated approach ensures continuity of treatment and enhances overall care management, irrespective of the student’s location.

In addition to facilitating traditional healthcare services, HealthLynked also empowers students with telemedicine access and mental health services. This feature enables students to consult with their home providers remotely or access mental health support when on-campus options are limited, thereby promoting consistent care and supporting overall well-being.

The benefits of HealthLynked extend beyond individual students to the universities themselves. By embracing this innovative solution, universities can offer students a personalized healthcare experience, earning recognition for prioritizing continuity and convenience in healthcare management. HealthLynked expands its member base and network, catering to thousands of new student users and securing its position as a leading healthcare integration platform.

In addition to student healthcare, the platform bridges the gap between telehealth and telemedicine, offering comprehensive clinical care based on patients’ medical histories. It expands mental health services and addresses gaps in women’s health, empowering patients with tailored care. HealthLynked facilitates at-home testing and routine screenings, enhancing early detection and preventative care.

Through remote monitoring and mobile health integration, patients can manage their health conveniently. The platform enables store-and-forward transmission of patient data and real-time remote consultations, ensuring flexibility and privacy in healthcare delivery. HealthLynked’s advanced network capabilities drive the expansion of telehealth services, providing a holistic and integrated healthcare experience for both patients and providers.

HealthLynked is a comprehensive solution that simplifies healthcare management for students, facilitates family involvement, and ensures continuity of care through telemedicine and coordinated specialist management. By leveraging HealthLynked, patients and healthcare professionals can expand well-being and streamline healthcare delivery across the nation, ushering in a new era of healthcare excellence.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

Life science professionals responsible for promotional review, marketing, labelling, communications, and compliance are invited to attend DGE’s 4th PRC Performance Optimization Summit being held in Philadelphia June 5-6, 2024. The most detailed industry event available on this subject, participants will focus in-depth on ways to ensure the best regulatory outcomes. DGE (Dynamic Global Events), a life science leader in organizing B2B events, strives to meet the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. DGE events specialize in offering a robust platform where professionals can network, connect, and explore business opportunities in a dynamic environment.

It is difficult to gather PRC input and maintain compliance when turnovers are high, when new technologies like AI come into play, and when team members meet virtually and regulatory decisions seem inconsistent. Industry experts will share breakthrough strategies on all these challenges, and more!

Topics of discussion:

• Raising company awareness of the PRC brand
• Maintaining CFL compliance
• Planning modular content updates
• Including AI-driven tasks into promotional review
• Training all team members to be high performers
• Incorporating strategies for new technologies like VR, mobile websites, and apps
• Integrating and managing a claims matrix

Attendees can learn and network with industry leaders and gain exclusive access to the event presentation information and contacts. The DGE summit provides all the strategies and tools that PRCs require to maintain compliance for the best regulatory results.

To learn more, please visit https://ibn.fm/98ZsO.

• SuperCom Ltd. is dedicated to serving government security needs for electronic tracking and monitoring of offenders
• The company recently reported its quarterly financial results, noting significant growth in revenues, profits, EBITDA, and operating income
• While SuperCom has focused on acquiring clients in California and other U.S. states, the company also has an international presence, European clients comprising significant part of its business

SuperCom (NASDAQ: SPCB) is widening its competitive edge in the electronic monitoring sector, resulting in revenue growth and a record profit for the company, reflected in the company’s recently released Q1 financial report (https://ibn.fm/rHLua).

“The substantial growth in our gross profit reflects the inherent quality and high-margin potential of our key projects and our successful progression through different stages of these projects,” SuperCom President and CEO Ordan Trabelsi stated in a news release announcing the company’s first quarter financial results.

“Typically, the initial stages of these projects involve higher expenses, which subsequently give way to higher gross margins as the projects advance, as demonstrated by this quarter’s results,” Ordan added. “Additionally, our EBITDA year-over-year has seen a remarkable 400% increase. This improvement is a testament to our rigorous management practices and dedication to effectively leveraging our core business infrastructure.”

SuperCom’s PureSecurity Suite of products provide an end-to-end electronic monitoring solution with state-of-the-art GPS tracking in real time, secured communication, and other monitoring technologies.

The company has applied its tracking and monitoring solutions to various needs. Still, its recent orientation has largely been on providing tracking for domestic violence (“DV”) offenders, helping court-administered house arrest monitoring.

The quarterly financial report notes that revenues increased by 8 percent to $6.9 million, gross profit increased 139 percent to $3.8 million, operating income entered positive territory with a $1.8 million increase, and EBITDA increased by 400% to $2 million.

The technological advances that define SuperCom’s PureSecurity Suite include its support network for programs that include smartphone integration, secure communication, advanced security, anti-tamper mechanisms, fingerprint biometrics, voice communication, unique touch screens, and extended battery life.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Hamptons and Tri-State real estate prices keep rising due to high demand and declining property inventory
• MTPP positioned to capitalize on current market conditions via strategy that fuses traditional real estate and PropTech investments
• MTPP recently initiated a Regulation D offering to raise up to $7.5 million for expansion of development projects in the Hamptons and PropTech investments

The Hamptons and broader Tri-State real estate markets continue their unprecedented upward trajectory, driven by the growing demand for properties amid a declining inventory. Mountain Top Properties (OTC: MTPP), a diversified real estate holding company, is strongly positioned to leverage current conditions by fusing traditional real estate development activities and innovative PropTech investments.

MTTP CEO Beau Kelley leads the company’s strategic direction and oversees its operations, leveraging his extensive experience in real estate acquisition and management across the Tri-State area and beyond. Through a partnership with his father Joseph Kelley – manager of On-Site Builder Construction – MTPP is favorably poised to identify emerging trends, secure opportunities, and deliver exceptional value to clients and investors.

Under the management of Joseph Kelley, On Site Builder Construction remains at the forefront of craftsmanship and excellence in the coveted Hamptons market. With over four decades of experience, Mr. Kelley has earned widespread acclaim for his meticulous attention to detail and unwavering commitment to delivering architecturally stunning custom homes – often featured in mainstream print and television media.

MTPP additionally incorporates PropTech investments as a cornerstone of its strategy, reflecting its commitment to innovation in the real estate industry.

PropTech, short for property technology, encompasses a wide range of digital innovations and solutions aimed at enhancing various aspects of real estate operations, from property management to construction to leasing. These investments may include technologies such as AI-driven analytics, virtual reality tours, smart home automation systems, and blockchain-powered property transactions. By harnessing the power of PropTech, MTPP aims to stay at the forefront of industry trends to unlock new opportunities for growth and innovation in the ever-evolving real estate landscape.

MTPP recently initiated a Regulation D offering to raise up to $7.5 million in capital to advance its strategic vision. This offering allows investors to participate in MTPP’s growth trajectory and capitalize on the lucrative opportunities in the Tri-State and prestigious Hamptons regions.

“Mountain Top Properties Inc. is pleased to announce it has filed a 506 Regulation D offering to add up to $7.5 million for the company’s real estate development plans,” said MTPP management in recent statements.

“The funds will be used to expand the company’s partnerships with On Site Builder Construction Co. Inc for the development of projects in the exclusive beachfront community known as the Hamptons; acquire additional projects; expand the marketing effort for the master lease of the 250,000 square foot facility in Pennsylvania; to acquire cutting edge property management operations; and to identify additional partners in the real estate and property technology space. The company expects to add proprietary technologies and best-in-class expertise to its growing list of assets.”

Mountain Top Properties is headquartered in Liverpool, New York with a satellite office in Sag Harbor, New York. Specializing in traditional real estate development and property management throughout the Tri-State area, the company enhances its core operations with strategic PropTech investments to provide investors with a diversified portfolio and consistent returns.

For more information, visit the company’s website at www.Mountain-Top-Properties.com.

NOTE TO INVESTORS: The latest news and updates relating to MTPP are available in the company’s newsroom at https://ibn.fm/MTPP